28821272|t|Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
28821272|a|The past decade witnessed the rapid development of adult B-lineage acute lymphoblastic leukemia (ALL) treatment. Beyond the development of chemotherapy regimens, immunotherapy is starting a new era with unprecedented complete remission (CR) rate. Targeting B-lineage-specific surface markers such as CD19, CD20, CD22, or CD52, immunotherapy has been demonstrating promising clinical results. Among the immunotherapeutic methods, naked monoclonal antibodies (mAbs), antibody-drug conjugate (ADC), bispecific T cell engager (BiTE), and chimeric antigen receptor (CAR) T cells are the main types. In this review, we will examine the emerging preclinical and clinical development on (1) anti-CD20 naked mAbs rituximab, ofatumumab, and obinutuzumab; (2) anti-CD19 ADCs SAR3419 and SGN-CD19A and anti-CD19 BiTE blinatumomab; (3) anti-CD22 naked mAb epratuzumab and anti-CD22 ADC inotuzumab ozogamicin; (4) anti-CD52 naked mAb alemtuzumab; and (5) anti-CD19 CAR T cells. We will discuss their efficacy, adverse effects, as well as future development.
28821272	32	40	patients	Species	9606
28821272	56	84	acute lymphoblastic leukemia	Disease	MESH:D054198
28821272	153	181	acute lymphoblastic leukemia	Disease	MESH:D054198
28821272	386	390	CD19	Gene	930
28821272	392	396	CD20	Gene	54474
28821272	398	402	CD22	Gene	933
28821272	407	411	CD52	Gene	1043
28821272	620	645	chimeric antigen receptor	Gene	9970
28821272	647	650	CAR	Gene	9970
28821272	774	778	CD20	Gene	54474
28821272	790	799	rituximab	Chemical	MESH:D000069283
28821272	801	811	ofatumumab	Chemical	MESH:C527517
28821272	817	829	obinutuzumab	Chemical	MESH:C543332
28821272	840	844	CD19	Gene	930
28821272	850	857	SAR3419	Chemical	MESH:C569646
28821272	862	865	SGN	Chemical	-
28821272	866	871	CD19A	Chemical	-
28821272	881	885	CD19	Gene	930
28821272	891	903	blinatumomab	Chemical	MESH:C510808
28821272	914	918	CD22	Gene	933
28821272	929	940	epratuzumab	Chemical	MESH:C448700
28821272	950	954	CD22	Gene	933
28821272	959	980	inotuzumab ozogamicin	Chemical	MESH:D000080045
28821272	991	995	CD52	Gene	1043
28821272	1006	1017	alemtuzumab	Chemical	MESH:D000074323
28821272	1032	1036	CD19	Gene	930
28821272	1037	1040	CAR	Gene	9970
28821272	Negative_Correlation	MESH:C543332	54474
28821272	Negative_Correlation	MESH:C527517	54474
28821272	Association	MESH:D000074323	1043
28821272	Negative_Correlation	MESH:D000069283	54474
28821272	Association	MESH:C569646	930
28821272	Association	MESH:D000080045	933
28821272	Negative_Correlation	MESH:D000069283	MESH:D054198
28821272	Association	MESH:C510808	930

